File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Small cell carcinoma of the esophagus

TitleSmall cell carcinoma of the esophagus
Authors
Keywordscarcinoma
esophagus
pathology
surgery
Issue Date1994
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
Citation
Cancer, 1994, v. 73 n. 12, p. 2894-2899 How to Cite?
AbstractBackground. Small cell carcinoma of the esophagus is regarded as having a poor prognosis with frequent systemic dissemination. Methods. A review of the records and histologic sections of 11 patients with primary small cell carcinoma of the esophagus seen in 11 years was undertaken. They were analyzed and compared with the more common squamous cell carcinomas and adenocarcinomas. Results. Small cell carcinoma of the esophagus constituted 1% of all esophageal tumors and was mainly located at the middle and lower thirds (90%) of the esophagus. Primary treatment consisted of tumor resection in five patients (46%), chemotherapy and radiotherapy in two (18%); surgical bypass in one (9%), radiotherapy after exploratory laparotomy in one (9%), intubation in one (9%), and no active intervention in one (9%). Two of the five resected tumors were Stage IIB disease, and three were Stage III disease. Five of the six patients in the non-resection group had distant metastases at presentation (45% of all patients). The median survival of patients who had chemotherapy (three of whom also had radiotherapy) was 16.7 months (range, 2.8-72 months) and was 2.2 months (range, 4 days to 9.1 months) for those with no chemotherapy. The overall median survival was 3.1 months for all patients. The prognosis was not significantly different from those with squamous cell carcinomas or adenocarcinomas. Conclusions. Small cell carcinoma of the esophagus should be regarded as a systemic disease, and multimodality treatment, including chemotherapy, should be used. Surgery may be offered in selected patients to manage local disease as part of a chemotherapy-based treatment program.
Persistent Identifierhttp://hdl.handle.net/10722/84118
ISSN
2015 Impact Factor: 5.649
2015 SCImago Journal Rankings: 3.188
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLaw, SYKen_HK
dc.contributor.authorFok, Men_HK
dc.contributor.authorLam, KYen_HK
dc.contributor.authorLoke, SLen_HK
dc.contributor.authorMa, LTen_HK
dc.contributor.authorWong, Jen_HK
dc.date.accessioned2010-09-06T08:49:09Z-
dc.date.available2010-09-06T08:49:09Z-
dc.date.issued1994en_HK
dc.identifier.citationCancer, 1994, v. 73 n. 12, p. 2894-2899en_HK
dc.identifier.issn0008-543Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/84118-
dc.description.abstractBackground. Small cell carcinoma of the esophagus is regarded as having a poor prognosis with frequent systemic dissemination. Methods. A review of the records and histologic sections of 11 patients with primary small cell carcinoma of the esophagus seen in 11 years was undertaken. They were analyzed and compared with the more common squamous cell carcinomas and adenocarcinomas. Results. Small cell carcinoma of the esophagus constituted 1% of all esophageal tumors and was mainly located at the middle and lower thirds (90%) of the esophagus. Primary treatment consisted of tumor resection in five patients (46%), chemotherapy and radiotherapy in two (18%); surgical bypass in one (9%), radiotherapy after exploratory laparotomy in one (9%), intubation in one (9%), and no active intervention in one (9%). Two of the five resected tumors were Stage IIB disease, and three were Stage III disease. Five of the six patients in the non-resection group had distant metastases at presentation (45% of all patients). The median survival of patients who had chemotherapy (three of whom also had radiotherapy) was 16.7 months (range, 2.8-72 months) and was 2.2 months (range, 4 days to 9.1 months) for those with no chemotherapy. The overall median survival was 3.1 months for all patients. The prognosis was not significantly different from those with squamous cell carcinomas or adenocarcinomas. Conclusions. Small cell carcinoma of the esophagus should be regarded as a systemic disease, and multimodality treatment, including chemotherapy, should be used. Surgery may be offered in selected patients to manage local disease as part of a chemotherapy-based treatment program.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741en_HK
dc.relation.ispartofCanceren_HK
dc.rightsCancer. Copyright © John Wiley & Sons, Inc.en_HK
dc.subjectcarcinomaen_HK
dc.subjectesophagusen_HK
dc.subjectpathologyen_HK
dc.subjectsurgeryen_HK
dc.titleSmall cell carcinoma of the esophagusen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0008-543X&volume=73&spage=2894&epage=2899&date=1994&atitle=Small+cell+carcinoma+of+the+esophagusen_HK
dc.identifier.emailLaw, SYK: slaw@hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.identifier.authorityLaw, SYK=rp00437en_HK
dc.identifier.authorityWong, J=rp00322en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/1097-0142(19940615)73:12<2894::AID-CNCR2820731204>3.0.CO;2-Men_HK
dc.identifier.pmid8199985-
dc.identifier.scopuseid_2-s2.0-0028230934en_HK
dc.identifier.hkuros3769en_HK
dc.identifier.volume73en_HK
dc.identifier.issue12en_HK
dc.identifier.spage2894en_HK
dc.identifier.epage2899en_HK
dc.identifier.isiWOS:A1994NQ40800003-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLaw, SYK=7202241293en_HK
dc.identifier.scopusauthoridFok, M=7005879262en_HK
dc.identifier.scopusauthoridLam, KY=7403657165en_HK
dc.identifier.scopusauthoridLoke, SL=7006559512en_HK
dc.identifier.scopusauthoridMa, LT=7403574642en_HK
dc.identifier.scopusauthoridWong, J=8049324500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats